Several cancer centers around the country are conducting clinical studies or creating registries to learn more about Covid-19, Covid-19 vaccinations and how they affect multiple myeloma patients. Some of these studies are observational clinical trials and seeking to gather information about patient outcomes. Follow the links below to learn more about these registries and studies.
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
The IMPACT Study is investigating how the virus affects the immune system and how people with risks for blood cancer may respond to COVID-19 and its emerging vaccines.
COVID-19 Antibody Testing of Recipients of Solid Organ Transplants and Patients with Chronic Diseases is being led by a team of researchers at Johns Hopkins Medicine.
The National Cancer Institute has awarded a five-year, $9.9 million grant to Emory investigators to study COVID-19 immune responses in patients with cancer or autoimmune diseases.
Since the COVID-19 vaccine approvals last month, people across the country have been lining up to receive their two-dose series. Vaccines have been hard to come by as shipments are sporadically making their way to states and local communities. Frontline health care workers and those 65 and older have been the first groups prioritized for the vaccine, but as more doses become available plans are underway to include additional groups at higher risk for contracting the virus, including cancer patients.
Troves of clinical trial data demonstrate the consistent success of COVID-19 vaccines across broad populations—but leave critical gaps in knowledge about unique groups. Early vaccine trials mostly excluded patients undergoing drug therapies that impact the immune system—like chemotherapy for cancer and certain treatments for inflammatory bowel disease (IBD).